Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Return on Sales (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Return on Sales for 16 consecutive years, with 0.11% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales rose 7019.0% year-over-year to 0.11%, compared with a TTM value of 0.21% through Dec 2025, up 26002.0%, and an annual FY2025 reading of 0.04%, up 17173.0% over the prior year.
  • Return on Sales was 0.11% for Q4 2025 at Arrowhead Pharmaceuticals, up from 0.06% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.68% in Q1 2025 and bottomed at 171.69% in Q3 2024.
  • Average Return on Sales over 5 years is 17.53%, with a median of 2.26% recorded in 2021.
  • The sharpest move saw Return on Sales tumbled -16480bps in 2024, then soared 17176bps in 2025.
  • Year by year, Return on Sales stood at 2.29% in 2021, then soared by 71bps to 0.67% in 2022, then tumbled by -5605bps to 38.12% in 2023, then tumbled by -84bps to 70.09% in 2024, then surged by 100bps to 0.11% in 2025.
  • Business Quant data shows Return on Sales for ARWR at 0.11% in Q4 2025, 0.06% in Q3 2025, and 6.43% in Q2 2025.